Amgen has announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Prolia (denosumab) for the treatment of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback